|
US20120196370A1
(en)
|
2010-12-03 |
2012-08-02 |
Fyodor Urnov |
Methods and compositions for targeted genomic deletion
|
|
EP2188384B1
(en)
|
2007-09-27 |
2015-07-15 |
Sangamo BioSciences, Inc. |
Rapid in vivo identification of biologically active nucleases
|
|
US8563314B2
(en)
*
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
US11235026B2
(en)
|
2007-09-27 |
2022-02-01 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating PD1
|
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
|
EP2206723A1
(en)
|
2009-01-12 |
2010-07-14 |
Bonas, Ulla |
Modular DNA-binding domains
|
|
US8956828B2
(en)
*
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
CA2783351C
(en)
|
2009-12-10 |
2021-09-07 |
Regents Of The University Of Minnesota |
Tal effector-mediated dna modification
|
|
ES2751916T3
(es)
*
|
2010-02-08 |
2020-04-02 |
Sangamo Therapeutics Inc |
Semidominios de escisión genomanipulados
|
|
BR112012020257A8
(pt)
*
|
2010-02-11 |
2018-02-14 |
Recombinetics Inc |
métodos e aparelhos para produzir artiodátilos transgênicos
|
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
|
CA2798988C
(en)
|
2010-05-17 |
2020-03-10 |
Sangamo Biosciences, Inc. |
Tal-effector (tale) dna-binding polypeptides and uses thereof
|
|
CA2805442C
(en)
|
2010-07-21 |
2020-05-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of an hla locus
|
|
AU2011312562B2
(en)
|
2010-09-27 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for inhibiting viral entry into cells
|
|
WO2012051343A1
(en)
|
2010-10-12 |
2012-04-19 |
The Children's Hospital Of Philadelphia |
Methods and compositions for treating hemophilia b
|
|
WO2012094132A1
(en)
|
2011-01-05 |
2012-07-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for gene correction
|
|
US10920242B2
(en)
|
2011-02-25 |
2021-02-16 |
Recombinetics, Inc. |
Non-meiotic allele introgression
|
|
US9528124B2
(en)
|
2013-08-27 |
2016-12-27 |
Recombinetics, Inc. |
Efficient non-meiotic allele introgression
|
|
EP3461896B1
(en)
|
2011-07-15 |
2023-11-29 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
|
WO2013016446A2
(en)
|
2011-07-25 |
2013-01-31 |
Sangamo Biosciences, Inc. |
Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
|
CA3186126A1
(en)
|
2011-09-21 |
2013-03-28 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of transgene expression
|
|
CA2852955C
(en)
|
2011-10-27 |
2021-02-16 |
Sangamo Biosciences, Inc. |
Methods and compositions for modification of the hprt locus
|
|
HK1200871A1
(en)
|
2011-11-16 |
2015-08-14 |
Sangamo Therapeutics, Inc. |
Modified dna-binding proteins and uses thereof
|
|
GB201122458D0
(en)
*
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
BR112014021104B1
(pt)
|
2012-02-29 |
2023-03-28 |
Sangamo Biosciences, Inc |
Proteína de fusão de ocorrência não natural compreendendo um domínio de ligação de dna de dedo de zinco manipulado que se liga a um gene htt, seu uso, método in vitro de modificação da expressão de um gene htt em uma célula, e método de geração de um sistema modelo para o estudo da doença de huntington
|
|
UA115875C2
(uk)
|
2012-05-02 |
2018-01-10 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Рослина помідора зі зменшеною активністю малатдегідрогенази та спосіб її отримання
|
|
BR112014027813A2
(pt)
|
2012-05-07 |
2017-08-08 |
Dow Agrosciences Llc |
métodos e composições para integração de transgenes direcionada mediada por nuclease
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
US20150225734A1
(en)
|
2012-06-19 |
2015-08-13 |
Regents Of The University Of Minnesota |
Gene targeting in plants using dna viruses
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
WO2014011901A2
(en)
|
2012-07-11 |
2014-01-16 |
Sangamo Biosciences, Inc. |
Methods and compositions for delivery of biologics
|
|
ES2697912T3
(es)
|
2012-07-11 |
2019-01-29 |
Sangamo Therapeutics Inc |
Métodos y composiciones para el tratamiento de enfermedades monogénicas
|
|
US10058078B2
(en)
|
2012-07-31 |
2018-08-28 |
Recombinetics, Inc. |
Production of FMDV-resistant livestock by allele substitution
|
|
AU2013308770B2
(en)
*
|
2012-08-29 |
2019-01-17 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
CA2884162C
(en)
|
2012-09-07 |
2020-12-29 |
Dow Agrosciences Llc |
Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
|
|
UA118090C2
(uk)
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
|
ES2824024T3
(es)
|
2012-10-10 |
2021-05-11 |
Sangamo Therapeutics Inc |
Compuestos modificadores de células T y usos de los mismos
|
|
EP2906602B1
(en)
|
2012-10-12 |
2019-01-16 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
|
MX367031B
(es)
|
2012-11-01 |
2019-08-02 |
Cellectis |
Plantas para la produccion de proteinas terapeuticas.
|
|
AU2013355327A1
(en)
*
|
2012-12-05 |
2015-06-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of metabolic disorders
|
|
US20140178561A1
(en)
|
2012-12-21 |
2014-06-26 |
Cellectis |
Potatoes with reduced cold-induced sweetening
|
|
US10676749B2
(en)
|
2013-02-07 |
2020-06-09 |
The General Hospital Corporation |
Tale transcriptional activators
|
|
CA2901676C
(en)
|
2013-02-25 |
2023-08-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
|
HK1220232A1
(zh)
|
2013-03-15 |
2017-04-28 |
怀特黑德生物医学研究院 |
用於神经变性疾病的细胞性发现平台
|
|
US10113162B2
(en)
|
2013-03-15 |
2018-10-30 |
Cellectis |
Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
KR102874079B1
(ko)
|
2013-03-15 |
2025-10-22 |
더 제너럴 하스피탈 코포레이션 |
Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용
|
|
EP2975942B1
(en)
|
2013-03-21 |
2018-08-08 |
Sangamo Therapeutics, Inc. |
Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
|
|
EP2981617B1
(en)
|
2013-04-04 |
2023-07-05 |
President and Fellows of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
|
WO2014165612A2
(en)
|
2013-04-05 |
2014-10-09 |
Dow Agrosciences Llc |
Methods and compositions for integration of an exogenous sequence within the genome of plants
|
|
EP2994531B1
(en)
*
|
2013-05-10 |
2018-03-28 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
US10260038B2
(en)
|
2013-05-10 |
2019-04-16 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
|
AU2014265331B2
(en)
|
2013-05-15 |
2019-12-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
|
EP3019595A4
(en)
*
|
2013-07-09 |
2016-11-30 |
|
THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS
|
|
WO2015031619A1
(en)
|
2013-08-28 |
2015-03-05 |
Sangamo Biosciences, Inc. |
Compositions for linking dna-binding domains and cleavage domains
|
|
WO2015033293A1
(en)
*
|
2013-09-04 |
2015-03-12 |
Csir |
Site-specific nuclease single-cell assay targeting gene regulatory elements to silence gene expression
|
|
WO2015057976A1
(en)
|
2013-10-17 |
2015-04-23 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
|
|
US9957526B2
(en)
|
2013-10-17 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
EP3060682B1
(en)
|
2013-10-25 |
2023-08-30 |
Livestock Improvement Corporation Limited |
Genetic markers and uses therefor
|
|
WO2015066638A2
(en)
|
2013-11-04 |
2015-05-07 |
Dow Agrosciences Llc |
Optimal maize loci
|
|
BR102014027442B1
(pt)
|
2013-11-04 |
2022-09-27 |
Dow Agrosciences Llc |
Molécula de ácido nucleico recombinante, uso de uma planta de milho, parte de planta de milho ou célula de planta de milho compreendendo a mesma e método para produzir uma célula vegetal transgênica compreendendo um dna de interesse
|
|
US10233465B2
(en)
|
2013-11-04 |
2019-03-19 |
Dow Agrosciences Llc |
Optimal soybean loci
|
|
EP3862434A1
(en)
|
2013-11-04 |
2021-08-11 |
Dow AgroSciences LLC |
Optimal soybean loci
|
|
KR20230054509A
(ko)
|
2013-11-07 |
2023-04-24 |
에디타스 메디신, 인코포레이티드 |
지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
|
|
CN105934524A
(zh)
|
2013-11-11 |
2016-09-07 |
桑格摩生物科学股份有限公司 |
用于治疗亨廷顿氏病的方法和组合物
|
|
DK3492593T3
(da)
*
|
2013-11-13 |
2021-11-08 |
Childrens Medical Center |
Nukleasemedieret regulering af genekspression
|
|
CA2930590C
(en)
*
|
2013-11-15 |
2021-02-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineering neural stem cells using homologous recombination
|
|
EP3757116A1
(en)
|
2013-12-09 |
2020-12-30 |
Sangamo Therapeutics, Inc. |
Methods and compositions for genome engineering
|
|
US10072066B2
(en)
|
2014-02-03 |
2018-09-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a beta thalessemia
|
|
JP6606088B2
(ja)
*
|
2014-02-24 |
2019-11-13 |
サンガモ セラピューティクス, インコーポレイテッド |
ヌクレアーゼ媒介性標的化組み込みのための方法および組成物
|
|
AU2015231353B2
(en)
|
2014-03-18 |
2020-11-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
|
US10507232B2
(en)
|
2014-04-02 |
2019-12-17 |
University Of Florida Research Foundation, Incorporated |
Materials and methods for the treatment of latent viral infection
|
|
WO2015164748A1
(en)
|
2014-04-24 |
2015-10-29 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (tale) proteins
|
|
RU2691102C2
(ru)
|
2014-05-08 |
2019-06-11 |
Сангамо Байосайенсиз, Инк. |
Способы и композиции для лечения болезни хантингтона
|
|
WO2015175642A2
(en)
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
|
EP3152319A4
(en)
|
2014-06-05 |
2017-12-27 |
Sangamo BioSciences, Inc. |
Methods and compositions for nuclease design
|
|
CA2952906A1
(en)
|
2014-06-20 |
2015-12-23 |
Cellectis |
Potatoes with reduced granule-bound starch synthase
|
|
BR112017000925B1
(pt)
|
2014-07-14 |
2023-10-10 |
Washington State University |
Método de reprodução de porcos, método para gerar um porco sem nenhuma célula espermatogônica funcional, método de produção de um macho receptor e método de produção de porcos
|
|
US9816074B2
(en)
|
2014-07-25 |
2017-11-14 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
|
|
US9757420B2
(en)
|
2014-07-25 |
2017-09-12 |
Sangamo Therapeutics, Inc. |
Gene editing for HIV gene therapy
|
|
US9616090B2
(en)
|
2014-07-30 |
2017-04-11 |
Sangamo Biosciences, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
|
US11261453B2
(en)
|
2014-09-12 |
2022-03-01 |
Whitehead Institute For Biomedical Research |
Cells expressing apolipoprotein E and uses thereof
|
|
CN106795488B
(zh)
|
2014-09-16 |
2021-03-30 |
桑格摩治疗股份有限公司 |
用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
|
|
WO2016073955A2
(en)
|
2014-11-06 |
2016-05-12 |
President And Fellows Of Harvard College |
Cells lacking b2m surface expression and methods for allogeneic administration of such cells
|
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
|
WO2016098078A2
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Dimerization switches and uses thereof
|
|
CN107109427B
(zh)
|
2014-12-23 |
2021-06-18 |
先正达参股股份有限公司 |
用于鉴定和富集包含位点特异性基因组修饰的细胞的方法和组合物
|
|
EP3247366A4
(en)
|
2015-01-21 |
2018-10-31 |
Sangamo Therapeutics, Inc. |
Methods and compositions for identification of highly specific nucleases
|
|
EP4335918A3
(en)
|
2015-04-03 |
2024-04-17 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
|
US10179918B2
(en)
|
2015-05-07 |
2019-01-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for increasing transgene activity
|
|
HK1254190A1
(zh)
|
2015-05-08 |
2019-07-12 |
President And Fellows Of Harvard College |
通用供体干细胞和相关方法
|
|
KR20170141217A
(ko)
*
|
2015-05-12 |
2017-12-22 |
상가모 테라퓨틱스, 인코포레이티드 |
유전자 발현의 뉴클레아제-매개된 조절
|
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
|
WO2017011519A1
(en)
|
2015-07-13 |
2017-01-19 |
Sangamo Biosciences, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US10837024B2
(en)
|
2015-09-17 |
2020-11-17 |
Cellectis |
Modifying messenger RNA stability in plant transformations
|
|
SI3352776T1
(sl)
|
2015-09-23 |
2025-08-29 |
Sangamo Therapeutics, Inc. |
Represorji Htt in njihove uporabe
|
|
JP2018532403A
(ja)
*
|
2015-09-29 |
2018-11-08 |
アジェノビア コーポレーション |
送達方法および組成物
|
|
MY189674A
(en)
|
2015-10-28 |
2022-02-24 |
Sangamo Therapeutics Inc |
Liver-specific constructs, factor viii expression cassettes and methods of use thereof
|
|
AU2016361350B2
(en)
|
2015-11-23 |
2023-04-06 |
Sangamo Therapeutics, Inc. |
Methods and compositions for engineering immunity
|
|
CN108699132B
(zh)
|
2015-12-18 |
2023-08-11 |
桑格摩生物治疗股份有限公司 |
Mhc细胞受体的靶向破坏
|
|
ES2983043T3
(es)
|
2015-12-18 |
2024-10-21 |
Sangamo Therapeutics Inc |
Alteración dirigida del receptor de células T
|
|
EP3402533B1
(en)
|
2016-01-15 |
2021-08-04 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of neurologic disease
|
|
EP4646936A3
(en)
|
2016-02-02 |
2025-11-19 |
Cellectis |
Modifying soybean oil composition through targeted knockout of the fad3a/b/c genes
|
|
US10724020B2
(en)
|
2016-02-02 |
2020-07-28 |
Sangamo Therapeutics, Inc. |
Compositions for linking DNA-binding domains and cleavage domains
|
|
US11421218B2
(en)
|
2016-03-23 |
2022-08-23 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
|
US11214789B2
(en)
|
2016-05-03 |
2022-01-04 |
Flodesign Sonics, Inc. |
Concentration and washing of particles with acoustics
|
|
CA3030783A1
(en)
|
2016-07-13 |
2018-01-18 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
|
UY40582A
(es)
|
2016-08-17 |
2024-01-15 |
Monsanto Technology Llc |
MÉTODOS, COMPOSICIONES y PLANTAS MEDIANTE LA MANIPULACIÓN DEL METABOLISMO DE GIBERELINA PARA AUMENTAR EL RENDIMIENTO COSECHABLE
|
|
US10975393B2
(en)
*
|
2016-08-24 |
2021-04-13 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
|
SG11201901531TA
(en)
|
2016-08-24 |
2019-03-28 |
Sangamo Therapeutics Inc |
Regulation of gene expression using engineered nucleases
|
|
US10960085B2
(en)
|
2016-09-07 |
2021-03-30 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
GB201617559D0
(en)
|
2016-10-17 |
2016-11-30 |
University Court Of The University Of Edinburgh The |
Swine comprising modified cd163 and associated methods
|
|
AU2017345430B2
(en)
|
2016-10-20 |
2024-09-05 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of Fabry disease
|
|
JP7108608B2
(ja)
|
2016-10-31 |
2022-07-28 |
サンガモ セラピューティクス, インコーポレイテッド |
造血幹細胞および前駆細胞におけるscid関連遺伝子の遺伝子修正
|
|
UY37482A
(es)
|
2016-11-16 |
2018-05-31 |
Cellectis |
Métodos para alterar el contenido de aminoácidos en plantas mediante mutaciones de desplazamiento de marco
|
|
MX2019006426A
(es)
|
2016-12-01 |
2019-08-14 |
Sangamo Therapeutics Inc |
Reguladores de tau, y composiciones y metodos para su administracion.
|
|
MA49610A
(fr)
|
2016-12-08 |
2020-05-27 |
Univ Case Western Reserve |
Procédés et compositions pour améliorer la production de myéline fonctionnelle
|
|
AU2018221730B2
(en)
|
2017-02-15 |
2024-06-20 |
Novo Nordisk A/S |
Donor repair templates multiplex genome editing
|
|
EP3615668B1
(en)
|
2017-04-25 |
2024-02-28 |
Cellectis |
Alfalfa with reduced lignin composition
|
|
US11820728B2
(en)
|
2017-04-28 |
2023-11-21 |
Acuitas Therapeutics, Inc. |
Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
CN110869497A
(zh)
|
2017-05-03 |
2020-03-06 |
桑格摩生物治疗股份有限公司 |
修饰囊性纤维化跨膜传导调节蛋白(cftr)基因的方法和组合物
|
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
|
CN111565730B
(zh)
|
2017-11-09 |
2024-09-17 |
桑格摩生物治疗股份有限公司 |
细胞因子诱导型含sh2蛋白(cish)基因的遗传修饰
|
|
RU2763798C1
(ru)
|
2017-12-23 |
2022-01-11 |
Рубиус Терапьютикс, Инк. |
Искусственные антигенпрезентирующие клетки и способы их применения
|
|
EP3740480B1
(en)
|
2018-01-17 |
2024-03-06 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
|
CN111741955B
(zh)
|
2018-01-17 |
2024-02-23 |
沃泰克斯药物股份有限公司 |
Dna-pk抑制剂
|
|
JP7483612B2
(ja)
|
2018-01-17 |
2024-05-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ゲノム編集効率を増加するためのキノキサリノン化合物、組成物、方法、およびキット
|
|
JP7275152B2
(ja)
|
2018-02-08 |
2023-05-17 |
サンガモ セラピューティクス, インコーポレイテッド |
操作された標的特異的なヌクレアーゼ
|
|
WO2019161151A1
(en)
|
2018-02-15 |
2019-08-22 |
Monsanto Technology Llc |
Compositions and methods for improving crop yields through trait stacking
|
|
UY38094A
(es)
|
2018-02-15 |
2019-10-01 |
Monsanto Technology Llc |
Métodos mejorados para la producción de semillas de maíz híbridas
|
|
WO2019204457A1
(en)
|
2018-04-18 |
2019-10-24 |
Sangamo Therapeutics, Inc. |
Zinc finger protein compositions for modulation of huntingtin (htt)
|
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
|
JP7541508B2
(ja)
|
2018-08-23 |
2024-08-28 |
サンガモ セラピューティクス, インコーポレイテッド |
操作された標的特異的な塩基エディター
|
|
WO2020061161A1
(en)
*
|
2018-09-18 |
2020-03-26 |
Sangamo Therapeutics, Inc. |
Programmed cell death 1 (pd1) specific nucleases
|
|
EP3852911B1
(en)
|
2018-09-21 |
2025-01-22 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
CN113226333A
(zh)
|
2018-10-02 |
2021-08-06 |
桑格摩生物治疗股份有限公司 |
用于调控Tau蛋白的方法和组合物
|
|
BR112021007301A2
(pt)
|
2018-10-18 |
2021-07-27 |
Intellia Therapeutics, Inc. |
composições e métodos para expressar fator ix
|
|
WO2020117852A1
(en)
|
2018-12-03 |
2020-06-11 |
Rubius Therapeutics, Inc. |
Artificial antigen presenting cells including hla-e and hla-g molecules and methods of use
|
|
US12274205B2
(en)
|
2018-12-12 |
2025-04-15 |
Monsanto Technology Llc |
Delayed harvest of short stature corn plants
|
|
US11453639B2
(en)
|
2019-01-11 |
2022-09-27 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
JP2022519410A
(ja)
|
2019-02-06 |
2022-03-24 |
サンガモ セラピューティクス, インコーポレイテッド |
ムコ多糖症i型の処置のための方法
|
|
CA3132167A1
(en)
|
2019-04-02 |
2020-10-08 |
Weston P. MILLER IV |
Methods for the treatment of beta-thalassemia
|
|
PE20212332A1
(es)
|
2019-04-23 |
2021-12-14 |
Sangamo Therapeutics Inc |
Moduladores de la expresioon del gen de marco de lectura abierto 72 del cromosoma 9 y usos de los mismos
|
|
AU2020376048A1
(en)
|
2019-11-01 |
2022-06-02 |
Sangamo Therapeutics, Inc. |
Compositions and methods for genome engineering
|
|
US20230279440A1
(en)
|
2020-05-06 |
2023-09-07 |
Cellectis S.A. |
Methods to genetically modify cells for delivery of therapeutic proteins
|
|
MX2023000614A
(es)
|
2020-07-16 |
2023-02-13 |
Acuitas Therapeutics Inc |
Lipidos cationicos para usarse en nanoparticulas lipidicas.
|
|
US12152251B2
(en)
|
2020-08-25 |
2024-11-26 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
EP4217479A1
(en)
|
2020-09-25 |
2023-08-02 |
Sangamo Therapeutics, Inc. |
Zinc finger fusion proteins for nucleobase editing
|
|
US20230416709A1
(en)
*
|
2020-11-06 |
2023-12-28 |
Editforce, Inc. |
Foki nuclease domain mutant
|
|
JP2024545942A
(ja)
|
2021-11-12 |
2024-12-16 |
モンサント テクノロジー エルエルシー |
植物の有限性を変えるための組成物及び方法
|
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
|
GB202118058D0
(en)
|
2021-12-14 |
2022-01-26 |
Univ Warwick |
Methods to increase yields in crops
|
|
IL313486A
(en)
|
2021-12-16 |
2024-08-01 |
Acuitas Therapeutics Inc |
Lipids for use in lipid nanoparticle formulations
|
|
IL313758A
(en)
|
2021-12-22 |
2024-08-01 |
Sangamo Therapeutics Inc |
Novel zinc finger fusion proteins for nuclear base editing
|
|
GB2621813A
(en)
|
2022-06-30 |
2024-02-28 |
Univ Newcastle |
Preventing disease recurrence in Mitochondrial replacement therapy
|
|
US12446503B2
(en)
|
2022-11-08 |
2025-10-21 |
Ohalo Genetics, Inc. |
Polyploid hybrid potato breeding
|
|
US12365908B2
(en)
|
2022-11-08 |
2025-07-22 |
Ohalo Genetics, Inc. |
Polyploid hybrid maize breeding
|
|
TW202448516A
(zh)
|
2023-02-03 |
2024-12-16 |
美商健臻公司 |
接合hsc特異性抗體的脂質奈米粒子及其用途
|
|
GB202314578D0
(en)
|
2023-09-22 |
2023-11-08 |
Univ Manchester |
Methods of producing homoplasmic modified plants or parts thereof
|